Small-molecule agents for cancer immunotherapy

Fang Wang; Kai Fu; Yujue Wang; Can Pan; Xueping Wang; Zeyu Liu; Chuan Yang; Ying Zheng; Xiaopeng Li; Yu Lu; Kenneth Kin Wah To; Chenglai Xia; Jianye Zhang; Zhi Shi; Zeping Hu; Min Huang; Liwu Fu

doi:10.1016/j.apsb.2023.12.010

Small-molecule agents for cancer immunotherapy

Fang Wang, Kai Fu, Yujue Wang, Can Pan, Xueping Wang, Zeyu Liu, Chuan Yang, Ying Zheng, Xiaopeng Li, Yu Lu, Kenneth Kin Wah To, Chenglai Xia, Jianye Zhang, Zhi Shi, Zeping Hu, Min Huang, Liwu Fu

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/chemokine signaling, and immune-related kinases have been extensively investigated. Monotherapy of small-molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance. Here, we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations.

Original language	English (US)
Pages (from-to)	905-952
Number of pages	48
Journal	Acta Pharmaceutica Sinica B
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.apsb.2023.12.010
State	Published - Mar 2024
Externally published	Yes

Keywords

Antitumor immunity
Cancer immunotherapy
Cytokine/chemokine signaling
Immune checkpoints
Metabolic pathways
Oncogenic signaling
Small-molecule agents
Tumor immune microenvironment

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics

Access to Document

10.1016/j.apsb.2023.12.010

Cite this

@article{83eb288c8f7e41529a1f31228a220c54,

title = "Small-molecule agents for cancer immunotherapy",

abstract = "Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/chemokine signaling, and immune-related kinases have been extensively investigated. Monotherapy of small-molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance. Here, we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations.",

keywords = "Antitumor immunity, Cancer immunotherapy, Cytokine/chemokine signaling, Immune checkpoints, Metabolic pathways, Oncogenic signaling, Small-molecule agents, Tumor immune microenvironment",

author = "Fang Wang and Kai Fu and Yujue Wang and Can Pan and Xueping Wang and Zeyu Liu and Chuan Yang and Ying Zheng and Xiaopeng Li and Yu Lu and To, {Kenneth Kin Wah} and Chenglai Xia and Jianye Zhang and Zhi Shi and Zeping Hu and Min Huang and Liwu Fu",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = mar,

doi = "10.1016/j.apsb.2023.12.010",

language = "English (US)",

volume = "14",

pages = "905--952",

journal = "Acta Pharmaceutica Sinica B",

issn = "2211-3835",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Small-molecule agents for cancer immunotherapy

AU - Wang, Fang

AU - Fu, Kai

AU - Wang, Yujue

AU - Pan, Can

AU - Wang, Xueping

AU - Liu, Zeyu

AU - Yang, Chuan

AU - Zheng, Ying

AU - Li, Xiaopeng

AU - Lu, Yu

AU - To, Kenneth Kin Wah

AU - Xia, Chenglai

AU - Zhang, Jianye

AU - Shi, Zhi

AU - Hu, Zeping

AU - Huang, Min

AU - Fu, Liwu

PY - 2024/3

Y1 - 2024/3

N2 - Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/chemokine signaling, and immune-related kinases have been extensively investigated. Monotherapy of small-molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance. Here, we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations.

AB - Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/chemokine signaling, and immune-related kinases have been extensively investigated. Monotherapy of small-molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance. Here, we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations.

KW - Antitumor immunity

KW - Cancer immunotherapy

KW - Cytokine/chemokine signaling

KW - Immune checkpoints

KW - Metabolic pathways

KW - Oncogenic signaling

KW - Small-molecule agents

KW - Tumor immune microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85181807533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181807533&partnerID=8YFLogxK

U2 - 10.1016/j.apsb.2023.12.010

DO - 10.1016/j.apsb.2023.12.010

M3 - Review article

C2 - 38486980

AN - SCOPUS:85181807533

SN - 2211-3835

VL - 14

SP - 905

EP - 952

JO - Acta Pharmaceutica Sinica B

JF - Acta Pharmaceutica Sinica B

IS - 3

ER -

Small-molecule agents for cancer immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this